{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T17:17:14Z","timestamp":1793207834851,"version":"4.5.0"},"reference-count":185,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T00:00:00Z","timestamp":1682035200000},"content-version":"am","delay-in-days":324,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R15 NS118352-01"],"award-info":[{"award-number":["R15 NS118352-01"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015257","name":"Northeastern University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015257","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-17-1-0329"],"award-info":[{"award-number":["W81XWH-17-1-0329"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["CDMRP W81XWH-17-1-0322"],"award-info":[{"award-number":["CDMRP W81XWH-17-1-0322"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA030989"],"award-info":[{"award-number":["R01DA030989"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA047130"],"award-info":[{"award-number":["R01DA047130"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.bcp.2022.115028","type":"journal-article","created":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T03:01:34Z","timestamp":1649041294000},"page":"115028","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"special_numbering":"C","title":["\u201cSelective\u201d serotonin 5-HT2A receptor antagonists"],"prefix":"10.1016","volume":"200","author":[{"given":"Austen B.","family":"Casey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond G.","family":"Booth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clinton E.","family":"Canal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6630","key":"10.1016\/j.bcp.2022.115028_b0005","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/387303a0","article-title":"Regulation of serotonin-2C receptor G-protein coupling by RNA editing","volume":"387","author":"Burns","year":"1997","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.bcp.2022.115028_b0010","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.tem.2017.04.002","article-title":"Htr2c Splice Variants and 5HT2CR-Mediated Appetite","volume":"28","author":"Isles","year":"2017","journal-title":"Trends Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.bcp.2022.115028_b0015","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1124\/mol.117.111062","article-title":"G protein-coupled receptors as targets for approved drugs: how many targets and how many drugs?","volume":"93","author":"Sriram","year":"2018","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2022.115028_b0020","doi-asserted-by":"crossref","unstructured":"G. Pandy-Szekeres, C. Munk, T.M. Tsonkov, S. Mordalski, K. Harpsoe, A.S. Hauser, et al., GPCRdb in 2018: adding GPCR structure models and ligands, Nucleic Acids Res. 46(D1) (2018) D440-D6.","DOI":"10.1093\/nar\/gkx1109"},{"issue":"5649","key":"10.1016\/j.bcp.2022.115028_b0025","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/272168a0","article-title":"Serotonergic component of neuroleptic receptors","volume":"272","author":"Leysen","year":"1978","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bcp.2022.115028_b0030","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0006-8993(79)90370-6","article-title":"Serotonergic facilitation of facial motoneuron excitation","volume":"169","author":"McCall]","year":"1979","journal-title":"Brain Res."},{"issue":"3","key":"10.1016\/j.bcp.2022.115028_b0035","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0026-895X(25)13812-1","article-title":"Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol","volume":"16","author":"Peroutka","year":"1979","journal-title":"Mol. Pharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2022.115028_b0040","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/0028-3908(86)90207-8","article-title":"Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine","volume":"25","author":"Bradley","year":"1986","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.bcp.2022.115028_b0060","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/BF00401468","article-title":"Mescaline and lysergic acid diethylamide (LSD) as discriminative stimuli","volume":"22","author":"Hirschhorn","year":"1971","journal-title":"Psychopharmacologia."},{"issue":"1","key":"10.1016\/j.bcp.2022.115028_b0045","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/S0022-3565(25)33038-7","article-title":"A drug discrimination analysis of lysergic acid diethylamide (LSD): in vivo agonist and antagonist effects of purported 5-hydroxytryptamine antagonists and of pirenperone, a LSD-antagonist","volume":"221","author":"Colpaert","year":"1982","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2-3","key":"10.1016\/j.bcp.2022.115028_b0050","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0014-2999(83)90464-8","article-title":"Antagonism of the effects of the hallucinogen DOM and the purported 5-HT agonist quipazine by 5-HT2 antagonists","volume":"91","author":"Glennon","year":"1983","journal-title":"Eur. J. Pharmacol."},{"issue":"25","key":"10.1016\/j.bcp.2022.115028_b0055","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1016\/0024-3205(84)90436-3","article-title":"Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents","volume":"35","author":"Glennon","year":"1984","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.bcp.2022.115028_b0065","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0022-3565(25)23298-0","article-title":"Serotonin-stimulated phosphoinositide turnover: mediation by the S2 binding site in rat cerebral cortex but not in subcortical regions","volume":"234","author":"Conn","year":"1985","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"9","key":"10.1016\/j.bcp.2022.115028_b0070","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1002\/j.1460-2075.1992.tb05427.x","article-title":"Cloning and functional characterization of the rat stomach fundus serotonin receptor","volume":"11","author":"Foguet","year":"1992","journal-title":"EMBO J."},{"issue":"4","key":"10.1016\/j.bcp.2022.115028_b0075","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/00001756-199204000-00014","article-title":"Structure of the mouse 5-HT1C, 5-HT2 and stomach fundus serotonin receptor genes","volume":"3","author":"Foguet","year":"1992","journal-title":"NeuroReport"},{"issue":"4","key":"10.1016\/j.bcp.2022.115028_b0080","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0026-895X(25)08969-2","article-title":"Molecular cloning, functional expression, and pharmacological characterization of a novel serotonin receptor (5-hydroxytryptamine2F) from rat stomach fundus","volume":"42","author":"Kursar","year":"1992","journal-title":"Mol. Pharmacol."},{"issue":"2\u20133","key":"10.1016\/j.bcp.2022.115028_b0085","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0014-5793(92)80936-B","article-title":"New mouse 5-HT2-like receptor. Expression in brain, heart and intestine","volume":"312","author":"Loric","year":"1992","journal-title":"FEBS Lett."},{"issue":"3","key":"10.1016\/j.bcp.2022.115028_b0090","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/0014-2999(84)90057-8","article-title":"The binding of serotonergic ligands to the porcine choroid plexus: characterization of a new type of serotonin recognition site","volume":"106","author":"Pazos","year":"1984","journal-title":"Eur. J. Pharmacol."},{"issue":"11","key":"10.1016\/j.bcp.2022.115028_b0095","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1073\/pnas.83.11.4086","article-title":"A unique serotonin receptor in choroid plexus is linked to phosphatidylinositol turnover","volume":"83","author":"Conn","year":"1986","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"6","key":"10.1016\/j.bcp.2022.115028_b0100","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0165-6147(93)90016-D","article-title":"A proposed new nomenclature for 5-HT receptors","volume":"14","author":"Humphrey","year":"1993","journal-title":"Trends Pharmacol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2022.115028_b0105","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S2215-0366(21)00386-2","article-title":"Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe","volume":"9","author":"Bugarski-Kirola","year":"2022","journal-title":"Lancet Psychiatry"},{"issue":"9916","key":"10.1016\/j.bcp.2022.115028_b0110","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial","volume":"383","author":"Cummings","year":"2014","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.bcp.2022.115028_b0115","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1474-4422(18)30039-5","article-title":"Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study","volume":"17","author":"Ballard","year":"2018","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.bcp.2022.115028_b0120","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa2034634","article-title":"Trial of Pimavanserin in Dementia-Related Psychosis","volume":"385","author":"Tariot","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bcp.2022.115028_b0125","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S2215-0366(21)00386-2","article-title":"Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe","volume":"9","author":"Bugarski-Kirola","year":"2022","journal-title":"Lancet Psychiatry."},{"issue":"16","key":"10.1016\/j.bcp.2022.115028_b0130","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1016\/j.neuron.2021.06.008","article-title":"Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo","volume":"109","author":"Shao","year":"2021","journal-title":"Neuron"},{"issue":"17","key":"10.1016\/j.bcp.2022.115028_b0135","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2022489118","article-title":"Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice","volume":"118","author":"Hesselgrave","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"11","key":"10.1016\/j.bcp.2022.115028_b0140","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","article-title":"Psychedelics Promote Structural and Functional Neural Plasticity","volume":"23","author":"Ly","year":"2018","journal-title":"Cell Rep."},{"issue":"6","key":"10.1016\/j.bcp.2022.115028_b0145","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1021\/acschemneuro.9b00493","article-title":"Psychedelics, but Not Ketamine, Produce Persistent Antidepressant-like Effects in a Rodent Experimental System for the Study of Depression","volume":"11","author":"Hibicke","year":"2020","journal-title":"ACS Chem. Neurosci."},{"issue":"3","key":"10.1016\/j.bcp.2022.115028_b0150","doi-asserted-by":"crossref","first-page":"109836","DOI":"10.1016\/j.celrep.2021.109836","article-title":"Prolonged epigenomic and synaptic plasticity alterations following single exposure to a psychedelic in mice","volume":"37","author":"de la Fuente Revenga","year":"2021","journal-title":"Cell Rep."},{"issue":"3","key":"10.1016\/j.bcp.2022.115028_b0155","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/0006-8993(77)90084-1","article-title":"Biochemical demonstration of dopaminergic receptors in rat and human brain using [3H]spiroperidol","volume":"136","author":"Fields","year":"1977","journal-title":"Brain Res."},{"issue":"2","key":"10.1016\/j.bcp.2022.115028_b0160","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0014-2999(78)90080-8","article-title":"3H-Spiroperidol labels serotonin receptors in rat cerebral cortex and hippocampus","volume":"49","author":"Creese","year":"1978","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.bcp.2022.115028_b0165","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1476-5381.1995.tb14977.x","article-title":"The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT2B) receptor gene products: comparison with 5-HT2A and 5-HT2C receptors","volume":"115","author":"Bonhaus","year":"1995","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2022.115028_b0170","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0304-3940(86)90492-1","article-title":"[125I]LSD labels 5-HT1C recognition sites in pig choroid plexus membranes. Comparison with [3H]mesulergine and [3H]5-HT binding","volume":"69","author":"Hoyer","year":"1986","journal-title":"Neurosci. Lett."},{"issue":"9","key":"10.1016\/j.bcp.2022.115028_b0175","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/0024-3205(81)90747-5","article-title":"Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors","volume":"28","author":"Leysen","year":"1981","journal-title":"Life Sci."},{"issue":"3","key":"10.1016\/j.bcp.2022.115028_b0180","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.cub.2016.12.030","article-title":"The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation","volume":"27","author":"Preller","year":"2017","journal-title":"Curr. Biol."},{"key":"10.1016\/j.bcp.2022.115028_b0185","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.35082","article-title":"Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor","volume":"7","author":"Preller","year":"2018","journal-title":"Elife."},{"issue":"13","key":"10.1016\/j.bcp.2022.115028_b0190","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1007\/s00213-017-4610-0","article-title":"Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation","volume":"234","author":"Kraehenmann","year":"2017","journal-title":"Psychopharmacology"},{"issue":"17","key":"10.1016\/j.bcp.2022.115028_b0195","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","article-title":"Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action","volume":"9","author":"Vollenweider","year":"1998","journal-title":"NeuroReport"},{"key":"10.1016\/j.bcp.2022.115028_b0200","article-title":"The Neurobiological Effect of 5-HT2AR Modulation","author":"Knudsen","year":"2020","journal-title":"ClinicalTrials.gov"},{"key":"10.1016\/j.bcp.2022.115028_b0205","unstructured":"M.E. Liechti, Role of the Serotonin 5-HT2A Receptor in Mescaline-induced Altered States of Consciousness (MDR). ClinicalTrials.gov; 2021. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04849013?term=ketanserin&draw=2&rank=8."},{"issue":"3","key":"10.1016\/j.bcp.2022.115028_b0210","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/BF00172788","article-title":"[3H]ketanserin labels 5-HT2 receptors and alpha 1-adrenoceptors in human and pig brain membranes","volume":"335","author":"Hoyer","year":"1987","journal-title":"Naunyn Schmiedebergs Arch Pharmacol."},{"issue":"16","key":"10.1016\/j.bcp.2022.115028_b0215","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1021\/jm980428x","article-title":"Synthesis, evaluation, and comparative molecular field analysis of 1-phenyl-3-amino-1,2,3,4-tetrahydronaphthalenes as ligands for histamine H(1) receptors","volume":"42","author":"Bucholtz","year":"1999","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2022.115028_b0220","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1254\/jjp.86.189","article-title":"Affinity of serotonin receptor antagonists and agonists to recombinant and native alpha1-adrenoceptor subtypes","volume":"86","author":"Yoshio","year":"2001","journal-title":"Jpn. J. Pharmacol."},{"issue":"Pt 3","key":"10.1016\/j.bcp.2022.115028_b0225","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1113\/jphysiol.1994.sp020263","article-title":"Alpha 1-adrenoceptors in rat dorsal raphe neurons: regulation of two potassium conductances","volume":"478","author":"Pan","year":"1994","journal-title":"J. Physiol."},{"issue":"4","key":"10.1016\/j.bcp.2022.115028_b0230","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1046\/j.1471-4159.2003.02044.x","article-title":"Stimulation of alpha1-adrenoceptors in the rat medial prefrontal cortex increases the local in vivo 5-hydroxytryptamine release: reversal by antipsychotic drugs","volume":"87","author":"Amargos-Bosch","year":"2003","journal-title":"J. Neurochem."},{"issue":"5","key":"10.1016\/j.bcp.2022.115028_b0235","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1017\/S1461145712001083","article-title":"Expression of alpha(1)-adrenergic receptors in rat prefrontal cortex: cellular co-localization with 5-HT(2A) receptors","volume":"16","author":"Santana","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"20","key":"10.1016\/j.bcp.2022.115028_b0240","doi-asserted-by":"crossref","first-page":"8850","DOI":"10.1523\/JNEUROSCI.22-20-08850.2002","article-title":"Convergent excitation of dorsal raphe serotonin neurons by multiple arousal systems (orexin\/hypocretin, histamine and noradrenaline)","volume":"22","author":"Brown","year":"2002","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.bcp.2022.115028_b0245","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/syn.10245","article-title":"Regulation of the release of serotonin in the dorsal raphe nucleus by alpha1 and alpha2 adrenoceptors","volume":"50","author":"Pudovkina","year":"2003","journal-title":"Synapse"},{"key":"10.1016\/j.bcp.2022.115028_b0250","doi-asserted-by":"crossref","unstructured":"J.E. Leysen, C.J. Niemegeers, J.M. Van Nueten, P.M. Laduron, [3H]Ketanserin (R 41 468), a selective 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role, Mol. Pharmacol. 21(2) (1982) 301\u2013314.","DOI":"10.1016\/S0026-895X(25)14623-3"},{"issue":"4","key":"10.1016\/j.bcp.2022.115028_b0255","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/PL00005075","article-title":"Selective visualization of rat brain 5-HT2A receptors by autoradiography with [3H]MDL 100,907","volume":"356","author":"L\u00f3pez-Gim\u00e9nez","year":"1997","journal-title":"Naunyn Schmiedebergs Arch Pharmacol."},{"issue":"6","key":"10.1016\/j.bcp.2022.115028_b0260","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1111\/j.1471-4159.1987.tb02444.x","article-title":"Characterization of two [3H]ketanserin recognition sites in rat striatum","volume":"49","author":"Roth","year":"1987","journal-title":"J. Neurochem."},{"issue":"6","key":"10.1016\/j.bcp.2022.115028_b0265","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0026-895X(25)13392-0","article-title":"Ketanserin binds to the monoamine transporter of chromaffin granules and of synaptic vesicles","volume":"33","author":"Darchen","year":"1988","journal-title":"Mol. Pharmacol."},{"issue":"10","key":"10.1016\/j.bcp.2022.115028_b0270","doi-asserted-by":"crossref","first-page":"5166","DOI":"10.1073\/pnas.93.10.5166","article-title":"Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter","volume":"93","author":"Erickson","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"2","key":"10.1016\/j.bcp.2022.115028_b0275","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S0022-3565(25)38366-7","article-title":"Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies","volume":"266","author":"Sorensen","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2022.115028_b0280","unstructured":"M. Dudley, A. Ogden, A. Carr, T. Nieduzak, J. Kehne, MDL 100,907, (+-\u03b1-(2,3-Dimethoxyphenyl)-1-[2-(4-Fluorophenylethyl)]-4-Piperidinemethanol), a Potent, Chiral, 5-HT2 Receptor Antagonist, in: Society for Neuroscience: 1990."},{"issue":"S1","key":"10.1016\/j.bcp.2022.115028_b0285","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1007\/BF02245008","article-title":"Electrophysiological, biochemical and behavioral evidence for 5-HT2 and 5-HT3 mediated control of dopaminergic function","volume":"112","author":"Palfreyman","year":"1993","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.bcp.2022.115028_b0290","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0022-3565(25)12956-X","article-title":"Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile","volume":"277","author":"Kehne","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"6400","key":"10.1016\/j.bcp.2022.115028_b0295","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/360161a0","article-title":"A single amino-acid difference confers major pharmacological variation between human and rodent 5-HT1B receptors","volume":"360","author":"Oksenberg","year":"1992","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.bcp.2022.115028_b0300","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/0014-5793(92)80705-L","article-title":"Site-directed mutagenesis of a single residue changes the binding properties of the serotonin 5-HT2 receptor from a human to a rat pharmacology","volume":"307","author":"Kao","year":"1992","journal-title":"FEBS Lett."},{"issue":"3","key":"10.1016\/j.bcp.2022.115028_b0305","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1124\/jpet.113.208637","article-title":"Molecular pharmacology and ligand docking studies reveal a single amino acid difference between mouse and human serotonin 5-HT2A receptors that impacts behavioral translation of novel 4-phenyl-2-dimethylaminotetralin ligands","volume":"347","author":"Canal","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1-2","key":"10.1016\/j.bcp.2022.115028_b0310","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.bbamem.2004.03.010","article-title":"Cholesterol modulates ligand binding and G-protein coupling to serotonin(1A) receptors from bovine hippocampus","volume":"1663","author":"Pucadyil","year":"2004","journal-title":"Biochim. Biophys. Acta, Mol. Cell. Biol. Lipids"},{"issue":"7329","key":"10.1016\/j.bcp.2022.115028_b0315","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature09648","article-title":"Structure of a nanobody-stabilized active state of the beta(2) adrenoceptor","volume":"469","author":"Rasmussen","year":"2011","journal-title":"Nature"},{"issue":"7366","key":"10.1016\/j.bcp.2022.115028_b0320","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nature10361","article-title":"Crystal structure of the beta2 adrenergic receptor-Gs protein complex","volume":"477","author":"Rasmussen","year":"2011","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bcp.2022.115028_b0325","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0006-2952(95)02122-1","article-title":"Radiolabelling of the human 5-HT2A receptor with an agonist, a partial agonist and an antagonist: effects on apparent agonist affinities","volume":"51","author":"Sleight","year":"1996","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2022.115028_b0330","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1146\/annurev-pharmtox-010510-100553","article-title":"Strategies to discover unexpected targets for drugs active at G protein-coupled receptors","volume":"51","author":"Allen","year":"2011","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"2","key":"10.1016\/j.bcp.2022.115028_b0335","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/sj.npp.1300819","article-title":"Evidence for the preferential involvement of 5-HT2A serotonin receptors in stress- and drug-induced dopamine release in the rat medial prefrontal cortex","volume":"31","author":"Pehek","year":"2006","journal-title":"Neuropsychopharmacology."},{"issue":"1","key":"10.1016\/j.bcp.2022.115028_b0340","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0022-3565(24)29327-7","article-title":"5-hydroxytryptamine2A receptor inverse agonists as antipsychotics","volume":"299","author":"Weiner","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.bcp.2022.115028_b0345","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/sj.npp.1300343","article-title":"The selective serotonin-2A receptor antagonist M100907 reverses behavioral deficits in dopamine transporter knockout mice","volume":"29","author":"Barr","year":"2004","journal-title":"Neuropsychopharmacology."},{"issue":"1","key":"10.1016\/j.bcp.2022.115028_b0350","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s002130050165","article-title":"Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice","volume":"129","author":"Gleason","year":"1997","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bcp.2022.115028_b0355","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.neuropharm.2013.01.007","article-title":"Support for 5-HT2C receptor functional selectivity in vivo utilizing structurally diverse, selective 5-HT2C receptor ligands and the 2,5-dimethoxy-4-iodoamphetamine elicited head-twitch response model","volume":"70","author":"Canal","year":"2013","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.bcp.2022.115028_b0360","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/BF01276460","article-title":"The selective 5-HT2A receptor antagonist MDL 100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse\u2013implications for psychosis","volume":"100","author":"Carlsson","year":"1995","journal-title":"J. Neural Transm. Gen. Sect."},{"issue":"1-2","key":"10.1016\/j.bcp.2022.115028_b0365","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/BF02245610","article-title":"5-HT modulation of auditory and visual sensorimotor gating: II. Effects of the 5-HT2A antagonist MDL 100,907 on disruption of sound and light prepulse inhibition produced by 5-HT agonists in Wistar rats","volume":"124","author":"Padich","year":"1996","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bcp.2022.115028_b0370","doi-asserted-by":"crossref","DOI":"10.3389\/fnrgo.2021.784576","article-title":"Human Cortical Serotonin 2A Receptor Occupancy by Psilocybin Measured Using [11C]MDL 100,907 Dynamic PET and a Resting-State fMRI-Based Brain Parcellation","volume":"2","author":"Barrett","year":"2022","journal-title":"Front. Neuroergonomics."},{"issue":"3","key":"10.1016\/j.bcp.2022.115028_b0375","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0893-133X(97)00044-4","article-title":"Time course of 5-HT2A receptor occupancy in the human brain after a single oral dose of the putative antipsychotic drug MDL 100,907 measured by positron emission tomography","volume":"17","author":"Grunder","year":"1997","journal-title":"Neuropsychopharmacology."},{"issue":"1","key":"10.1016\/j.bcp.2022.115028_b0380","first-page":"123","article-title":"M-100907 (Aventis)","volume":"2","author":"de Paulis","year":"2001","journal-title":"Curr. Opin. Invest. Drugs"},{"issue":"10","key":"10.1016\/j.bcp.2022.115028_b0385","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1007\/s11064-014-1293-3","article-title":"On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis","volume":"39","author":"Hacksell","year":"2014","journal-title":"Neurochem. Res."},{"issue":"2","key":"10.1016\/j.bcp.2022.115028_b0390","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1124\/jpet.105.097006","article-title":"Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phen ylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist","volume":"317","author":"Vanover","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.bcp.2022.115028_b0395","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41594-018-0180-z","article-title":"Structures of the 5-HT2A receptor in complex with the antipsychotics risperidone and zotepine","volume":"26","author":"Kimura","year":"2019","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.bcp.2022.115028_b0400","article-title":"A new class of serotonin 5-HT2A \/5-HT2C receptor inverse agonists: Synthesis, molecular modeling, in vitro and in vivo pharmacology of novel 2-aminotetralins","author":"Casey","year":"2021","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2022.115028_b0405","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.euroneuro.2020.05.004","article-title":"Pimavanserin exhibits serotonin 5-HT2A receptor inverse agonism for Galphai1- and neutral antagonism for Galphaq\/11-proteins in human brain cortex","volume":"36","author":"Muneta-Arrate","year":"2020","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"4","key":"10.1016\/j.bcp.2022.115028_b0410","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1017\/S1092852916000407","article-title":"Mechanism of action of pimavanserin in Parkinson's disease psychosis: targeting serotonin 5HT2A and 5HT2C receptors","volume":"21","author":"Stahl","year":"2016","journal-title":"CNS Spectr."},{"issue":"6","key":"10.1016\/j.bcp.2022.115028_b0415","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19m12928","article-title":"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin in Patients With Major Depressive Disorder and an Inadequate Response to Therapy (CLARITY)","volume":"80","author":"Fava","year":"2019","journal-title":"J. Clin. Psychiatry"},{"issue":"8","key":"10.1016\/j.bcp.2022.115028_b0420","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1038\/npp.2009.29","article-title":"5-HT(2A) and 5-HT(2C) receptors exert opposing effects on locomotor activity in mice","volume":"34","author":"Halberstadt","year":"2009","journal-title":"Neuropsychopharmacology."},{"issue":"13","key":"10.1016\/j.bcp.2022.115028_b0425","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1038\/npp.2012.139","article-title":"Clozapine-induced locomotor suppression is mediated by 5-HT2A receptors in the forebrain","volume":"37","author":"McOmish","year":"2012","journal-title":"Neuropsychopharmacology."},{"issue":"13","key":"10.1016\/j.bcp.2022.115028_b0430","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1523\/JNEUROSCI.0112-04.2004","article-title":"Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens","volume":"24","author":"De Deurwaerdere","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bcp.2022.115028_b0435","doi-asserted-by":"crossref","first-page":"107915","DOI":"10.1016\/j.neuropharm.2019.107915","article-title":"Lorcaserin bidirectionally regulates dopaminergic function site-dependently and disrupts dopamine brain area correlations in rats","volume":"166","author":"De Deurwaerd\u00e8re","year":"2020","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.bcp.2022.115028_b0440","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/adb.12137","article-title":"Serotonin2C receptors modulate dopamine transmission in the nucleus accumbens independently of dopamine release: behavioral, neurochemical and molecular studies with cocaine","volume":"20","author":"Cathala","year":"2015","journal-title":"Addict. Biol."},{"issue":"4","key":"10.1016\/j.bcp.2022.115028_b0445","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/npp.2009.176","article-title":"Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis","volume":"35","author":"Meltzer","year":"2010","journal-title":"Neuropsychopharmacology."},{"issue":"2","key":"10.1016\/j.bcp.2022.115028_b0450","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.sleep.2010.10.004","article-title":"Pimavanserin tartrate, a 5-HT(2A) receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteers","volume":"12","author":"Ancoli-Israel","year":"2011","journal-title":"Sleep Med."},{"issue":"7","key":"10.1016\/j.bcp.2022.115028_b0455","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1001\/archpsyc.1992.01820070032005","article-title":"Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects","volume":"49","author":"Farde","year":"1992","journal-title":"Arch. Gen. Psychiatry"},{"issue":"5","key":"10.1016\/j.bcp.2022.115028_b0460","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.bmcl.2015.01.017","article-title":"(11)C-labeling and preliminary evaluation of pimavanserin as a 5-HT2A receptor PET-radioligand","volume":"25","author":"Andersen","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"3","key":"10.1016\/j.bcp.2022.115028_b0465","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0006-2952(78)90233-2","article-title":"a ligand of choice for neuroleptic receptors. 1. Kinetics and characteristics of in vitro binding","volume":"27","author":"Leysen","year":"1978","journal-title":"Biochem. Pharmacol."},{"issue":"4","key":"10.1016\/j.bcp.2022.115028_b0470","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd1062","article-title":"Discovering risperidone: the LSD model of psychopathology","volume":"2","author":"Colpaert","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.bcp.2022.115028_b0475","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S0026-895X(25)12558-3","article-title":"Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist","volume":"27","author":"Leysen","year":"1985","journal-title":"Mol. Pharmacol."},{"issue":"Suppl 7","key":"10.1016\/j.bcp.2022.115028_b0480","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1097\/00005344-198500077-00002","article-title":"Pharmacology of potent and selective S2-serotonergic antagonists","volume":"7","author":"Janssen","year":"1985","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.bcp.2022.115028_b0485","unstructured":"Kennis JEJV, J. Novel 1,2-benzisoxadol-3-yl and 1,2-benzisothiazol-3-yl derivatives, 1985."},{"issue":"12","key":"10.1016\/j.bcp.2022.115028_b0495","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.5665\/sleep.2230","article-title":"Sleep deprivation increases cerebral serotonin 2A receptor binding in humans","volume":"35","author":"Elmenhorst","year":"2012","journal-title":"Sleep"},{"issue":"11","key":"10.1016\/j.bcp.2022.115028_b0500","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1093\/cercor\/bhp022","article-title":"Medial prefrontal cortex 5-HT(2A) density is correlated with amygdala reactivity, response habituation, and functional coupling","volume":"19","author":"Fisher","year":"2009","journal-title":"Cereb. Cortex"},{"issue":"5","key":"10.1016\/j.bcp.2022.115028_b0505","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/0028-3908(83)90147-8","article-title":"Inhibition of 5-hydroxytryptamine-mediated behaviour by the putative 5-HT2 antagonist pirenperone","volume":"22","author":"Green","year":"1983","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.bcp.2022.115028_b0510","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.cell.2018.01.001","article-title":"5-HT2C Receptor Structures Reveal the Structural Basis of GPCR Polypharmacology","volume":"172","author":"Peng","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2022.115028_b0515","doi-asserted-by":"crossref","unstructured":"J.A. Ballesteros, H. Weinstein, Integrated Methods for the Construction of Three-Dimensional Models and Computational Probing of Structure-Function Relations in G Protein-Coupled Receptors Methods in Neuroscience. 25 (1995) 366\u2013428.","DOI":"10.1016\/S1043-9471(05)80049-7"},{"issue":"5","key":"10.1016\/j.bcp.2022.115028_b0520","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1124\/mol.58.5.877","article-title":"Differential modes of agonist binding to 5-hydroxytryptamine(2A) serotonin receptors revealed by mutation and molecular modeling of conserved residues in transmembrane region 5","volume":"58","author":"Shapiro","year":"2000","journal-title":"Mol. Pharmacol."},{"issue":"8","key":"10.1016\/j.bcp.2022.115028_b0525","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1021\/acs.jmedchem.8b00836","article-title":"Aminergic GPCR-Ligand Interactions: A Chemical and Structural Map of Receptor Mutation Data","volume":"62","author":"Vass","year":"2019","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bcp.2022.115028_b0530","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.cell.2020.08.024","article-title":"Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor","volume":"182","author":"Kim","year":"2020","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.bcp.2022.115028_b0535","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S0026-895X(25)13677-8","article-title":"Site-directed mutagenesis of the serotonin 5-hydroxytrypamine2 receptor: identification of amino acids necessary for ligand binding and receptor activation","volume":"43","author":"Wang","year":"1993","journal-title":"Mol. Pharmacol."},{"issue":"7354","key":"10.1016\/j.bcp.2022.115028_b0540","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nature10236","article-title":"Structure of the human histamine H1 receptor complex with doxepin","volume":"475","author":"Shimamura","year":"2011","journal-title":"Nature"},{"issue":"6132","key":"10.1016\/j.bcp.2022.115028_b0545","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1126\/science.1232807","article-title":"Structural basis for molecular recognition at serotonin receptors","volume":"340","author":"Wang","year":"2013","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.bcp.2022.115028_b0550","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.cell.2016.12.033","article-title":"Crystal Structure of an LSD-Bound Human Serotonin Receptor","volume":"168","author":"Wacker","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bcp.2022.115028_b0555","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41593-021-00971-w","article-title":"Structure-based design of a novel third-generation antipsychotic drug lead with potential antidepressant properties","volume":"25","author":"Chen","year":"2022","journal-title":"Nat. Neurosci."},{"issue":"1","key":"10.1016\/j.bcp.2022.115028_b0560","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1021\/acs.chemrev.6b00177","article-title":"GPCR Dynamics: Structures in Motion","volume":"117","author":"Latorraca","year":"2017","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bcp.2022.115028_b0565","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.50279","article-title":"Common activation mechanism of class A GPCRs","volume":"8","author":"Zhou","year":"2019","journal-title":"Elife."},{"issue":"1","key":"10.1016\/j.bcp.2022.115028_b0570","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1021\/acschemneuro.6b00124","article-title":"Mutagenesis Analysis Reveals Distinct Amino Acids of the Human Serotonin 5-HT2c Receptor Underlying the Pharmacology of Distinct Ligands","volume":"8","author":"Liu","year":"2017","journal-title":"ACS Chem. Neurosci."},{"issue":"2","key":"10.1016\/j.bcp.2022.115028_b0575","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0026-895X(25)09924-9","article-title":"Species variations in transmembrane region V of the 5-hydroxytryptamine type 2A receptor alter the structure-activity relationship of certain ergolines and tryptamines","volume":"45","author":"Johnson","year":"1994","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2022.115028_b0580","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0026-895X(25)09149-7","article-title":"Contribution of a helix 5 locus to selectivity of hallucinogenic and nonhallucinogenic ligands for the human 5-hydroxytryptamine2A and 5-hydroxytryptamine2C receptors: direct and indirect effects on ligand affinity mediated by the same locus","volume":"50","author":"Almaula","year":"1996","journal-title":"Mol. Pharmacol."},{"issue":"9","key":"10.1016\/j.bcp.2022.115028_b0585","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/s41401-019-0217-9","article-title":"Structural insight into the serotonin (5-HT) receptor family by molecular docking, molecular dynamics simulation and systems pharmacology analysis","volume":"40","author":"Wang","year":"2019","journal-title":"Acta Pharmacol. Sin."},{"issue":"6","key":"10.1016\/j.bcp.2022.115028_b0590","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1124\/mol.109.059204","article-title":"Position 5.46 of the serotonin 5-HT2A receptor contributes to a species-dependent variation for the 5-HT2C agonist (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-o ne: impact on selectivity and toxicological evaluation","volume":"76","author":"Miller","year":"2009","journal-title":"Mol. Pharmacol."},{"issue":"21","key":"10.1016\/j.bcp.2022.115028_b0595","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1093\/hmg\/10.21.2319","article-title":"Understanding human disease mutations through the use of interspecific genetic variation","volume":"10","author":"Miller","year":"2001","journal-title":"Hum. Mol. Genet."},{"issue":"25","key":"10.1016\/j.bcp.2022.115028_b0600","doi-asserted-by":"crossref","first-page":"14672","DOI":"10.1074\/jbc.271.25.14672","article-title":"Mapping the binding site pocket of the serotonin 5-Hydroxytryptamine2A receptor. Ser3.36(159) provides a second interaction site for the protonated amine of serotonin but not of lysergic acid diethylamide or bufotenin","volume":"271","author":"Almaula","year":"1996","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.bcp.2022.115028_b0605","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1124\/mol.107.039255","article-title":"Assessment of the roles of serines 5.43(239) and 5.46(242) for binding and potency of agonist ligands at the human serotonin 5-HT2A receptor","volume":"72","author":"Braden","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2022.115028_b0610","unstructured":"BL Roth D. Contract NO2MH80002, in: Psychoactive Drug Screening Program database. National Institute of Mental Health, 2012."},{"issue":"4","key":"10.1016\/j.bcp.2022.115028_b0615","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd1346","article-title":"Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia","volume":"3","author":"Roth","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"issue":"15","key":"10.1016\/j.bcp.2022.115028_b0620","doi-asserted-by":"crossref","first-page":"8078","DOI":"10.1073\/pnas.93.15.8078","article-title":"Brain lipids that induce sleep are novel modulators of 5-hydroxytrypamine receptors","volume":"93","author":"Huidobro-Toro","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"25","key":"10.1016\/j.bcp.2022.115028_b0625","doi-asserted-by":"crossref","first-page":"14115","DOI":"10.1073\/pnas.94.25.14115","article-title":"Unique allosteric regulation of 5-hydroxytryptamine receptor-mediated signal transduction by oleamide","volume":"94","author":"Thomas","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"6579","key":"10.1016\/j.bcp.2022.115028_b0630","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1126\/science.abl8615","article-title":"Structure-based discovery of nonhallucinogenic psychedelic analogs","volume":"375","author":"Cao","year":"2022","journal-title":"Science"},{"issue":"6165","key":"10.1016\/j.bcp.2022.115028_b0635","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1126\/science.1244142","article-title":"Serial femtosecond crystallography of G protein-coupled receptors","volume":"342","author":"Liu","year":"2013","journal-title":"Science"},{"issue":"31","key":"10.1016\/j.bcp.2022.115028_b0640","doi-asserted-by":"crossref","first-page":"8223","DOI":"10.1073\/pnas.1700891114","article-title":"Structural insights into the extracellular recognition of the human serotonin 2B receptor by an antibody","volume":"114","author":"Ishchenko","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"1","key":"10.1016\/j.bcp.2022.115028_b0645","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-20221-0","article-title":"Structure of the dopamine D2 receptor in complex with the antipsychotic drug spiperone","volume":"11","author":"Im","year":"2020","journal-title":"Nat. Commun."},{"issue":"25","key":"10.1016\/j.bcp.2022.115028_b0650","doi-asserted-by":"crossref","first-page":"5084","DOI":"10.1021\/jm980452a","article-title":"Spiperone: influence of spiro ring substituents on 5-HT2A serotonin receptor binding","volume":"41","author":"Metwally","year":"1998","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2022.115028_b0655","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0022-3565(24)39293-6","article-title":"A highly conserved aspartic acid (Asp-155) anchors the terminal amine moiety of tryptamines and is involved in membrane targeting of the 5-HT(2A) serotonin receptor but does not participate in activation via a \u201csalt-bridge disruption\u201d mechanism","volume":"293","author":"Kristiansen","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"7-8","key":"10.1016\/j.bcp.2022.115028_b0660","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.drudis.2012.01.001","article-title":"Can we discover pharmacological promiscuity early in the drug discovery process?","volume":"17","author":"Peters","year":"2012","journal-title":"Drug Discov Today."},{"issue":"21","key":"10.1016\/j.bcp.2022.115028_b0665","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/S1359-6446(05)03632-9","article-title":"Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development","volume":"10","author":"Whitebread","year":"2005","journal-title":"Drug Discov Today."},{"issue":"5","key":"10.1016\/j.bcp.2022.115028_b0670","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/sj.bjp.0702632","article-title":"RS-127445: a selective, high affinity, orally bioavailable 5-HT2B receptor antagonist","volume":"127","author":"Bonhaus","year":"1999","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2022.115028_b0675","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0028-3908(01)00054-5","article-title":"SB-243213; a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety","volume":"41","author":"Wood","year":"2001","journal-title":"Neuropharmacology"},{"issue":"4-5","key":"10.1016\/j.bcp.2022.115028_b0680","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0028-3908(97)00038-5","article-title":"SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist","volume":"36","author":"Kennett","year":"1997","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.bcp.2022.115028_b0685","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1476-5381.1996.tb15208.x","article-title":"In vitro and in vivo profile of SB 206553, a potent 5-HT2C\/5-HT2B receptor antagonist with anxiolytic-like properties","volume":"117","author":"Kennett","year":"1996","journal-title":"Br. J. Pharmacol."},{"issue":"14","key":"10.1016\/j.bcp.2022.115028_b0690","doi-asserted-by":"crossref","first-page":"6166","DOI":"10.1021\/acs.jmedchem.7b00385","article-title":"Utilization of an Active Site Mutant Receptor for the Identification of Potent and Selective Atypical 5-HT2C Receptor Agonists","volume":"60","author":"Carpenter","year":"2017","journal-title":"J. Med. Chem."},{"issue":"25","key":"10.1016\/j.bcp.2022.115028_b0695","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1021\/jm00077a003","article-title":"Three-dimensional quantitative structure-activity relationships of 5-HT receptor binding data for tetrahydropyridinylindole derivatives: a comparison of the Hansch and CoMFA methods","volume":"36","author":"Agarwal","year":"1993","journal-title":"J. Med. Chem."},{"issue":"15","key":"10.1016\/j.bcp.2022.115028_b0700","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1021\/jm981094e","volume":"42","author":"Ravina","year":"1999","journal-title":"J. Med. Chem."},{"issue":"5480","key":"10.1016\/j.bcp.2022.115028_b0705","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1126\/science.289.5480.739","article-title":"Crystal structure of rhodopsin: A G protein-coupled receptor","volume":"289","author":"Palczewski","year":"2000","journal-title":"Science"},{"issue":"7168","key":"10.1016\/j.bcp.2022.115028_b0710","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nature06325","article-title":"Crystal structure of the human beta2 adrenergic G-protein-coupled receptor","volume":"450","author":"Rasmussen","year":"2007","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.bcp.2022.115028_b0715","doi-asserted-by":"crossref","first-page":"11441","DOI":"10.1074\/jbc.M111675200","article-title":"Evidence for a model of agonist-induced activation of 5-hydroxytryptamine 2A serotonin receptors that involves the disruption of a strong ionic interaction between helices 3 and 6","volume":"277","author":"Shapiro","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2022.115028_b0720","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/(SICI)1098-2396(200002)35:2<144::AID-SYN7>3.0.CO;2-K","article-title":"Agonist high and low affinity state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT(2A) and 5-HT(2C) receptors","volume":"35","author":"Egan","year":"2000","journal-title":"Synapse"},{"issue":"9","key":"10.1016\/j.bcp.2022.115028_b0725","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1248\/bpb.b12-00401","article-title":"Mechanism of inverse agonist action of sarpogrelate at the constitutively active mutant of human 5-HT2A receptor revealed by molecular modeling","volume":"35","author":"Hossain","year":"2012","journal-title":"Biol. Pharm. Bull."},{"issue":"21","key":"10.1016\/j.bcp.2022.115028_b0730","doi-asserted-by":"crossref","first-page":"9442","DOI":"10.1021\/acs.jmedchem.8b00675","article-title":"Where Do Recent Small Molecule Clinical Development Candidates Come From?","volume":"61","author":"Brown","year":"2018","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2022.115028_b0735","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1021\/acs.jmedchem.8b01048","article-title":"Virtual Chemical Libraries","volume":"62","author":"Walters","year":"2019","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2022.115028_b0740","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1359-6446(00)01596-8","article-title":"High-throughput chemistry and structure-based design: survival of the smartest","volume":"6","author":"Bailey","year":"2001","journal-title":"Drug Discov Today."},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2022.115028_b0745","first-page":"S7","article-title":"Towards the development of universal, fast and highly accurate docking\/scoring methods: a long way to go","volume":"153","author":"Moitessier","year":"2008","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2022.115028_b0750","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2174\/157340911795677602","article-title":"Molecular docking: a powerful approach for structure-based drug discovery","volume":"7","author":"Meng","year":"2011","journal-title":"Curr. Comput. Aided Drug Des."},{"issue":"7893","key":"10.1016\/j.bcp.2022.115028_b0755","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41586-021-04220-9","article-title":"Synthon-based ligand discovery in virtual libraries of over 11 billion compounds","volume":"601","author":"Sadybekov","year":"2022","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.bcp.2022.115028_b0760","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1080\/07391102.2015.1062802","article-title":"Molecular modelling of human 5-hydroxytryptamine receptor (5-HT2A) and virtual screening studies towards the identification of agonist and antagonist molecules","volume":"34","author":"Gandhimathi","year":"2016","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"10","key":"10.1016\/j.bcp.2022.115028_b0765","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1080\/07391102.2020.1768900","article-title":"Revealing the interaction modes of 5-HT2A receptor antagonists and the Structure-Based virtual screening from FDA and TCMNP database","volume":"39","author":"Wang","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"10","key":"10.1016\/j.bcp.2022.115028_b0770","doi-asserted-by":"crossref","DOI":"10.3390\/biom9100556","article-title":"Pharmacophore Directed Screening of Agonistic Natural Molecules Showing Affinity to 5HT2C Receptor","volume":"9","author":"Veeramachaneni","year":"2019","journal-title":"Biomolecules."},{"issue":"13","key":"10.1016\/j.bcp.2022.115028_b0775","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1016\/j.bmc.2009.05.003","article-title":"Identification of novel serotonin 2C receptor ligands by sequential virtual screening","volume":"17","author":"Ahmed","year":"2009","journal-title":"Bioorg. Med. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2022.115028_b0780","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1021\/acs.jmedchem.5b01631","article-title":"Structure-Based Discovery of Novel and Selective 5-Hydroxytryptamine 2B Receptor Antagonists for the Treatment of Irritable Bowel Syndrome","volume":"59","author":"Zhou","year":"2016","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.bcp.2022.115028_b0785","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/cmdc.201000186","article-title":"HTS and rational drug design to generate a class of 5-HT(2C)-selective ligands for possible use in schizophrenia","volume":"5","author":"Kozikowski","year":"2010","journal-title":"ChemMedChem"},{"issue":"6361","key":"10.1016\/j.bcp.2022.115028_b0790","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1126\/science.aan5468","article-title":"D4 dopamine receptor high-resolution structures enable the discovery of selective agonists","volume":"358","author":"Wang","year":"2017","journal-title":"Science"},{"issue":"7743","key":"10.1016\/j.bcp.2022.115028_b0795","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41586-019-0917-9","article-title":"Ultra-large library docking for discovering new chemotypes","volume":"566","author":"Lyu","year":"2019","journal-title":"Nature"},{"issue":"7800","key":"10.1016\/j.bcp.2022.115028_b0800","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41586-020-2027-0","article-title":"Virtual discovery of melatonin receptor ligands to modulate circadian rhythms","volume":"579","author":"Stein","year":"2020","journal-title":"Nature"},{"issue":"7890","key":"10.1016\/j.bcp.2022.115028_b0805","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41586-021-04175-x","article-title":"Structures of the sigma2 receptor enable docking for bioactive ligand discovery","volume":"600","author":"Alon","year":"2021","journal-title":"Nature"},{"issue":"45","key":"10.1016\/j.bcp.2022.115028_b0810","doi-asserted-by":"crossref","first-page":"16044","DOI":"10.1021\/ja508394x","article-title":"A functional selectivity mechanism at the serotonin-2A GPCR involves ligand-dependent conformations of intracellular loop 2","volume":"136","author":"Perez-Aguilar","year":"2014","journal-title":"J. Am. Chem. Soc."},{"issue":"3","key":"10.1016\/j.bcp.2022.115028_b0815","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.neuron.2007.01.008","article-title":"Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior","volume":"53","author":"Gonz\u00e1lez-Maeso","year":"2007","journal-title":"Neuron"},{"issue":"4","key":"10.1016\/j.bcp.2022.115028_b0820","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1124\/mol.114.097022","article-title":"Detection of new biased agonists for the serotonin 5-HT2A receptor: modeling and experimental validation","volume":"87","author":"Mart\u00ed-Solano","year":"2015","journal-title":"Mol. Pharmacol."},{"issue":"4","key":"10.1016\/j.bcp.2022.115028_b0825","doi-asserted-by":"crossref","first-page":"e1002473","DOI":"10.1371\/journal.pcbi.1002473","article-title":"Ligand-dependent conformations and dynamics of the serotonin 5-HT(2A) receptor determine its activation and membrane-driven oligomerization properties","volume":"8","author":"Shan","year":"2012","journal-title":"PLoS Comput. Biol."},{"issue":"2","key":"10.1016\/j.bcp.2022.115028_b0830","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1021\/ci100375b","article-title":"Predicted structures and dynamics for agonists and antagonists bound to serotonin 5-HT2B and 5-HT2C receptors","volume":"51","author":"Kim","year":"2011","journal-title":"J. Chem. Inf. Model."},{"issue":"17","key":"10.1016\/j.bcp.2022.115028_b0835","doi-asserted-by":"crossref","first-page":"8028","DOI":"10.1021\/acs.jmedchem.9b00723","article-title":"A Comparative Assessment Study of Known Small-Molecule Keap1-Nrf2 Protein-Protein Interaction Inhibitors: Chemical Synthesis, Binding Properties, and Cellular Activity","volume":"62","author":"Tran","year":"2019","journal-title":"J. Med. Chem."},{"issue":"7\u20138","key":"10.1016\/j.bcp.2022.115028_b0840","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/dta.1333","article-title":"Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model","volume":"4","author":"Canal","year":"2012","journal-title":"Drug Test. Anal."},{"issue":"2","key":"10.1016\/j.bcp.2022.115028_b0845","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/dta.2222","article-title":"Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775)","volume":"10","author":"Brandt","year":"2018","journal-title":"Drug Test. Anal."},{"issue":"6","key":"10.1016\/j.bcp.2022.115028_b0850","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0969-8051(99)00022-0","article-title":"Characterization of radioactive metabolites of 5-HT2A receptor PET ligand [18F]altanserin in human and rodent","volume":"26","author":"Tan","year":"1999","journal-title":"Nucl. Med. Biol."},{"issue":"2","key":"10.1016\/j.bcp.2022.115028_b0855","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S0022-3565(25)12346-X","article-title":"Pharmacologic characterization of the human 5-hydroxytryptamine2B receptor: evidence for species differences","volume":"276","author":"Wainscott","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.bcp.2022.115028_b0860","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s00210-001-0505-y","article-title":"Characterization of phospholipase C activity at h5-HT2C compared with h5-HT2B receptors: influence of novel ligands upon membrane-bound levels of [3H]phosphatidylinositols","volume":"365","author":"Cussac","year":"2002","journal-title":"Naunyn Schmiedebergs Arch Pharmacol."},{"key":"10.1016\/j.bcp.2022.115028_b0865","series-title":"Drugs as Tools in Neurotransmitter Research","article-title":"Use of 5-HT Receptor Agonists and Antagonists for the Characterization of Their Respective Receptor Sites","author":"Leysen","year":"1989"},{"issue":"3","key":"10.1016\/j.bcp.2022.115028_b0870","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/PL00005058","article-title":"Characterization of human serotonin 1D and 1B receptors using [3H]-GR-125743, a novel radiolabelled serotonin 5HT1D\/1B receptor antagonist","volume":"356","author":"Dom\u00e9nech","year":"1997","journal-title":"Naunyn Schmiedebergs Arch Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2022.115028_b0875","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0026-895X(25)08894-7","article-title":"Human gene S31 encodes the pharmacologically defined serotonin 5-hydroxytryptamine1E receptor","volume":"42","author":"Zgombick","year":"1992","journal-title":"Mol. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2022.115028_b0880","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1073\/pnas.90.2.408","article-title":"Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase","volume":"90","author":"Adham","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"1-2","key":"10.1016\/j.bcp.2022.115028_b0885","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF02245606","article-title":"Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding","volume":"124","author":"Schotte","year":"1996","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bcp.2022.115028_b0890","first-page":"440","article-title":"Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications","volume":"178","author":"Toll","year":"1998","journal-title":"NIDA Res. Monogr."},{"issue":"12","key":"10.1016\/j.bcp.2022.115028_b0895","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1002\/j.1460-2075.1995.tb07280.x","article-title":"The 5-HT4 receptor: molecular cloning and pharmacological characterization of two splice variants","volume":"14","author":"Gerald","year":"1995","journal-title":"EMBO J."},{"issue":"6","key":"10.1016\/j.bcp.2022.115028_b0900","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/sj.bjp.0701946","article-title":"Functional characterisation of the human cloned 5-HT7 receptor (long form); antagonist profile of SB-258719","volume":"124","author":"Thomas","year":"1998","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2022.115028_b0905","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/sj.bjp.0701336","article-title":"Cloning, expression and pharmacology of a truncated splice variant of the human 5-HT7 receptor (h5-HT7b)","volume":"122","author":"Jasper","year":"1997","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2022.115028_b0910","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1124\/jpet.105.087809","article-title":"Differential effects of the 5-hydroxytryptamine (5-HT)1A receptor inverse agonists Rec 27\/0224 and Rec 27\/0074 on electrophysiological responses to 5-HT1A receptor activation in rat dorsal raphe nucleus and hippocampus in vitro","volume":"315","author":"Corradetti","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1\u20132","key":"10.1016\/j.bcp.2022.115028_b0915","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0014-2999(86)90335-3","article-title":"Further validation of in vivo and in vitro pharmacological procedures for assessing the alpha 2\/alpha 1-selectivity of test compounds: (1). Alpha-adrenoceptor antagonists","volume":"129","author":"Megens","year":"1986","journal-title":"Eur. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2022.115028_b0920","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0026-895X(25)09495-7","article-title":"Cloning, expression, and pharmacological characterization of a human alpha 2B-adrenergic receptor","volume":"38","author":"Weinshank","year":"1990","journal-title":"Mol. Pharmacol."},{"issue":"6319","key":"10.1016\/j.bcp.2022.115028_b0925","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/350614a0","article-title":"Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1","volume":"350","author":"Sunahara","year":"1991","journal-title":"Nature"},{"issue":"15","key":"10.1016\/j.bcp.2022.115028_b0930","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.1073\/pnas.81.15.4983","article-title":"Psychotomimetic opiate receptors labeled and visualized with (+)-[3H]3-(3-hydroxyphenyl)-N-(1-propyl)piperidine","volume":"81","author":"Largent","year":"1984","journal-title":"Proc. Natl. Acad. Sci. U S A"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295222001228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295222001228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T21:28:52Z","timestamp":1777411732000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295222001228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":185,"alternative-id":["S0006295222001228"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2022.115028","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u201cSelective\u201d serotonin 5-HT2A receptor antagonists","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2022.115028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115028"}}